2022. Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s65. DOI:https://doi.org/10.25251/skin.6.supp.65.